Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas

Sponsor
Klinikum Stuttgart
Study ID
NCT05515068
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Bone Sarcoma
  • Bone Tumor
  • Chondroblastic Osteosarcoma
  • Clear Cell Osteosarcoma
  • Conventional Central Osteosarcoma of Bone
  • Conventional Osteosarcoma
  • Extraskeletal Osteosarcoma
  • Fibroblastic Osteosarcoma
  • High Grade Sarcoma
  • High Grade Surface Osteosarcoma
  • Low Grade Central Osteosarcoma
  • Osseous Angiosarcoma
  • Osseous Dedifferentiated Chondrosarcoma
  • Osseous Fibrosarcoma
  • Osseous Leiomyosarcoma
  • Osseous Mesenchymal Chondrosarcoma
  • Osseous Sarcoma
  • Osseous Tumor
  • Osteoblastic Osteosarcoma
  • Osteosarcoma
  • Parosteal Osteosarcoma
  • Periosteal Osteosarcoma
  • Recurrent Osteosarcoma
  • Small Cell Osteosarcoma
  • Telangiectatic Osteosarcoma
  • Undifferentiated Pleomorphic Sarcoma

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Study Details

The Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas (COSS-Registry) is a non-interventional, multicentric, international, clinical and epidemiologic patient registry. The COSS-Registry collects key data on osteosarcomas or biologically related bone sarcomas. With that data collection we want to gain new scientific insights and results about this tumor disease, prognosis, surveillance and long-term effects. Besides the data collection we would also like to foster the collection of biomaterial (tumor specimen and blood samples) for scientific research. The stored material will be used to perform cell and molecular biological analyses to identify the causes of osteosarcoma, the prognosis and possible new treatment options. As a starting point the donated biomaterial of registered patients will be analyzed firstly for the presence of a tumor predisposition by germline mutations. In case of detected genetic variations that are related to the tumor disease and which may affect the patient's health and follow-up care (because of the potentially increased risk of developing other malignant tumors), affected patients will be informed and referred to genetic counseling. Registry patients will be asked at the time of diagnosis if they wish to be informed about germline variants detected as part of the study procedures.

Key Dates

First listed
Aug 25, 2022
Start date
Sep 30, 2022
Status verified
Aug 2022
Primary completion
Mar 31, 2032
Completion
Mar 31, 2032

Study Design

Enrollment
1,000 participants (estimated)

Primary Outcome Measure

Data Collection [ Time Frame: 20 years (There will be continous subgroup analyses through study completion.) ]

Related Studies